LinkBlog
6 Golden Rules for Conquering Performance Anxiety by David Leisner
Freedom from Fear's On Target Summer/Fall 2007 newsletter - an anxiety & depression resource (PDF)
Switching between monoamine oxidase inhibitors (MAOIs) and SSRI or tricyclic antidepressants (.doc format)
Switching between tricyclic, SSRI and related antidepressants (.doc format)
blog roll
- Agoraphobia
- Anxiety 2 Calm
-
Anxious Living : An Exploration
into Social Anxiety - Dare to Dream
- Dear Tobacco
-
Dr. Deborah Serani's:
Psychological Perspectives - Fast Weight Loss?
- Finding the Confidence
- GNIF Brain Blogger
- Legacy of War
- Mental Health Minutes
- My Brain: My Friend, My Enemy
- My Wife Has Agoraphobia!
- Neurophilosophy
- PTSD Combat
- The Happiness Guy
- The Last Psychiatrist
- The Trouble With Spikol
-
WebMD: Anxiety and
Stress Management - We Worry: A Blog for the Anxious
recommended links
Depression Is Real Coalition
-
ABIL: Agoraphobics Building
Independant Lives -
Agoraphobia and Panic
Disorder Foundation -
Anxiety Disorders Association
of America - Anxiety Network Australia
- Anxiety-Panic.Com
- AnxietyZone
- Army Behavioral Health
- BrainPhysics - OCD
-
Canadian Network for Mood
and Anxiety Treatments - Children of Hoarders
- Choices in Mental Health (UK)
-
Dart Foundation: Gateway to PTSD
information -
David Baldwin's
Trauma Information Pages - EMDR Institute, Inc.
- EMDR Network Japan
- Fear of Flying course (free)
- Healthy Minds
- Information for People with Anxiety Disorders
- Internet Guide to REBT, CBT
- Living with a Brain Disorder
- Morita Therapy
- Mayo Clinic : Depression
- Mayo Clinic : GAD
- Mayo Clinic : OCD
- Mayo Clinic : Panic Attacks
- Mayo Clinic : PTSD
- Mayo Clinic : Social Anxiety
-
Medicines.org.uk - Anxiety &
Depression guides - Mind-Your-Mind Canada
- National Center for PTSD
-
National Institute of Mental
Health (NIMH) - No Such Thing As Crazy
- OCD Action, UK
- OCD Ireland
- Obsessive Compulsive Foundation
- Open Minds, Open Doors
- Paniccure.com
- Partners With PTSD
- Prescription Drug Information
- Psychiatric Service Dog Society
- PsychNews
-
Rational Emotive Behavior
Therapy (REBT) - Sane Australia
-
Shyness & Social Anxiety
Service of Australia -
Social Phobia/Social Anxiety
Association - Social Anxiety Support board
-
South African Depression &
Anxiety Group - Suicide Prevention Help
-
tAPir - the Anxiety Panic
internet resource -
The Panic Center (Free
CBT based programs) - The School of OCD
- UN-WHO Drug Trials Database
- U.S. Army Behavioral Health - PTSD
"just don't smoke"
Yul Brynner
- Menthol cigarettes harder to quit
- Secondhand smoke in cars serious threat to kid's health
- Starting smoking young increases addiction risk
-
Smoking doesn't slim girls;
stunts boys' growth - 40 reasons why you should quit smoking
- Pregnant smokers 'prime' their kids to smoke
- Smoking related coronary artery disease quickly reversed if young smokers quit
- Not ready to quit? Try cutting back
- Half smoking again within year of lung cancer surgery
- Cutting back 'compensation' increases toxin load per cigarette
- Tobacco companies upped nicotine level 11% since 1998
- Workplace passive smoke increases lung cancer risk
- Hooked by genes: The DNA sequences cigarette companies love
- Smoking causes long lasting changes to brain's bio chemistry
- Nicotine receptor stimulant trebles the odds of stopping smoking
- Bupropion, nortriptyline double chances of quitting
- Nicotine's powerful role in reinforcing smoking
- Pregnant smokers raise child's risk of stroke, heart attack
- Smoking linked to pancreatic cancer
- Neurobiology of Smokers' Cravings
- 'Low cancer risk' cigarettes as deadly as regular kind
- Quitting reduces lung cancer death risk by 70%
- Fetal nicotine exposure linked to teen attention problems
- Outdoor second-hand smoke exposure can harm
- Response to day's first cigarette predicts ease of quitting
- 'Healthy' children of smoking parents aren't really so healthy
- Children of smokers have up to five times higher levels of a nicotine toxin
- Smoking increases risk of dementia
- Smoking kills even after quitting
- Antenatal second hand smoke exposure increases child's psychological problems
- Smoking could kill 1 billion this century: WHO
- Just 1 cigarette can lead to nicotine addiction
- Smokers less likely to survive early stage lung cancer
- Smokeless tobacco delivers carcinogens more efficiently than cigarettes!
anti torture campaign
- Torture experts write APA policy
- [APA] still rocked by torture debate
- Petition for psychologists
- AMA president says APA "did not accurately represent our ethical guidelines"
- Psychologists Aiding Torturers
-
Annual conference endorses
APA's torture policy :( - Physicians for Human Rights call on Congress to vote No on Military Commissions Bill
-
Torture is a Form of Trauma;
Trauma Causes PTSD - Psychoanalysts' association condemns torture use
- Humiliating, inhumane or degrading treatment IS torture
- Two American psychologists accused of war crimes. U.S. DoD investigating.
- DoD report proves psychologists central to POW/detainee abuse (pdf)
- 40 psychologists demand APA change policy on torture (pdf)
- Did the American Psychological Association turn a blind eye to torture for medicine precribing rights?
- Will psychologists still abet torture?
Deputy Army Chief of Staff for Intelligence, Lt. General John (Jeff) Kimmons, has stated that no actionable intelligence had been obtained through abusive interrogation methods in the last 5 years.
monument, Monmouth County
New Jersey.
Anesthetic points way to faster-acting antidepressants
Experimental medication ketamine relieves depression in just hours — points to targets for new medications
A new study by U.S. National Institute of Mental Health researchers has revealed more about how the medication ketamine relieves symptoms of depression in hours instead of the weeks or months it takes for current antidepressants to work.
While ketamine itself probably won't come into use as an antidepressant because of its side effects, the new finding moves scientists considerably closer to understanding how to develop faster-acting antidepressant medications
Ketamine blocks a receptor called NMDA on brain cells, an earlier NIMH study in humans had shown, but the new study in mice shows that this is an intermediate step. It turns out that blocking NMDA increases the activity of another receptor, AMPA, and that this boost in AMPA is crucial for ketamine's rapid antidepressant actions.
"Our research is showing us how to develop medications that get at the biological roots of depression. This new finding is a major step toward learning how to improve treatment for the millions of Americans with this debilitating disorder; toward eliminating the weeks of suffering and uncertainty they have to endure while they wait for their medications to work," said NIH Director Elias Zerhouni, M.D.
Almost 15 million American adults have a depressive disorder. During the long wait to begin feeling the effects of conventional medications, patients may worsen, raising the risk of suicide for some. Depressive disorders also affect children and adolescents.
By aiming new medications at more direct molecular targets, such as NMDA or AMPA, scientists may be able to bypass some of the steps through which current antidepressants indirectly exert their effects - a roundabout route that accounts for the long time it takes for patients to begin feeling better with the conventional medications.
While ketamine appears to achieve this, it is unlikely to become a new treatment for depression because of the side effects it can cause in humans, including hallucinations. It is approved as an anesthetic by the Food and Drug Administration at much higher doses than those given in the study, but its use is limited because it may cause hallucinations during recovery from anesthesia.
Both NMDA and AMPA are receptors for the neurotransmitter glutamate, one of the chemical messengers that enable brain cells to communicate with each other. The glutamate system has been implicated in depression recently, leading to efforts to unravel its molecular machinery in search of abnormalities and of better targets for antidepressant medications.
This focus on the glutamate system is a departure from the thinking that led to currently available antidepressants, which are thought to relieve depression through a lengthy trickle-down process of biochemical reactions that affect the circuitry underlying depression.
The fact that NMDA and AMPA receptors are part of the glutamate system and that targeting them directly led to such rapid, sustained relief of depression-like behaviors in this study - and that a single dose of ketamine did the same in humans in the earlier study - suggests that they are probably the key targets for antidepressant medications.
"In any other illness of depression's magnitude, patients aren't expected to just accept that their treatments won't start helping them for weeks or months. The value of our research on compounds like ketamine is that it tells us where to look for more precise targets for new kinds of medications that can close the gap," said NIMH Director Thomas R. Insel, MD. "We're making tremendous progress."
To conduct the new study, researchers induced depression-like behaviors in mice; for example, the mice gave up after being forced to engage in hopeless tasks, such as prolonged swimming. A dose of ketamine reversed the depression-like behaviors for at least two weeks.
When the researchers gave the mice a substance that blocks the AMPA receptor beforehand, ketamine was not able to reverse the depression-like behaviors. The boost in AMPA thus appears to be a necessary ingredient for ketamine's antidepressant effects.
In a related experiment, the scientists used two different compounds instead of ketamine to try to block just one part of the NMDA receptor, an even more precise target. These other compounds also reduced depressive behaviors, suggesting that it may be feasible to develop other fast-acting antidepressants without ketamine's side effects.
"Today's antidepressant medications eventually end up doing the same thing, but they go about it the long way around, with a lot of biochemical steps that take time. Now we've shown what the key targets are and that we can get at them rapidly," said Zarate. "Ketamine probably can't become the medication of choice, but this research is leading to some very real possibilities for a whole new generation of antidepressant medications."
Related articles...
Maeng S, Zarate Jr. CA, Du J, et al. Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors Biol. Psychiatry 2007; doi:10.1016/j.biopsych.2007.05.028 []